News

not found

AIDS Can Be Ended by 2030 With Investments in Prevention and Treatment, UN Says

It is possible to end AIDS by 2030 if countries demonstrate the political will to invest in prevention and treatment and adopt non-discriminatory laws, the United Nations said on Thursday. In 2022, an estimated 39 million people around the world were living with HIV, according to UNAIDS, the United Nations AIDS program. HIV can progress to AIDS if left untreated. "We have a solution if we follow the leadership of countries that have forged strong political commitment to put people first and invest in evidence-based HIV prevention and treatment programmes," UNAIDS said in a report published on Thursday. It said an effective response to HIV also meant adopting non-discriminatory laws and empowering community networks, among other initiatives. People living with HIV or AIDS in many countries face stigma, discrimination and violence. "Progress has been strongest in the countries and regions that have the most financial investments, such as in eastern and southern Africa, where new HIV infections have been reduced by 57% since 2010," the report said. It added, however, that there has been a steep increase in new infections in eastern Europe and central Asia, as well as in the Middle East and North Africa. "These trends are due primarily to a lack of HIV prevention services for marginalized and key populations and the barriers posed by punitive laws and social discrimination," it said. Last year, 1.3 million people became newly infected with HIV and 630,000 died from AIDS-related illnesses, according to UNAIDS.

  • 27 July, 14:58
  • Read more
not found

Investigating Associations of Omega-3 Fatty Acids, Lung Function Decline, and Airway Obstruction

Rationale: Inflammation contributes to lung function decline and the development of chronic obstructive pulmonary disease. Omega-3 fatty acids have anti-inflammatory properties and may benefit lung health. Objectives: Investigate associations of omega-3 fatty acids with lung function decline and incident airway obstruction in diverse adults from general population cohorts. Methods: Complementary study designs: (1) longitudinal study of plasma phospholipid omega-3 fatty acids and repeated FEV1 and FVC measures in the National Heart, Lung, and Blood Institute Pooled Cohorts Study, and (2) two-sample Mendelian Randomization (MR) study of genetically predicted omega-3 fatty acids and lung function parameters. Measurements and Main Results: The longitudinal study found that higher omega-3 fatty acid levels were associated with attenuated lung function decline in 15,063 participants, with the largest effect sizes for the most metabolically downstream omega-3 fatty acid, docosahexaenoic acid (DHA). An increase in DHA of 1% of total fatty acids was associated with an attenuation of 1.4 mL/year for FEV1 (95% confidence interval [CI] 1.1–1.8) and 2.0 mL/year for FVC (95% CI 1.6–2.4) and a 7% lower incidence of spirometry-defined airway obstruction (95% CI 0.89–0.97). DHA associations persisted across sexes, smoking histories, and Black, white and Hispanic participants, with the largest magnitude associations in former smokers and Hispanics. The MR study showed similar trends towards positive associations of genetically predicted downstream omega-3 fatty acids with FEV1 and FVC. Conclusions: The longitudinal and MR studies provide evidence supporting beneficial effects of higher levels of downstream omega-3 fatty acids, especially DHA, on lung health.

  • 24 July, 17:47
  • Read more
not found

EMA statement on ongoing review of GLP-1 receptor agonists

EMA’s safety committee, the PRAC, is reviewing data on the risk of suicidal thoughts and thoughts of self-harm with medicines known as GLP-1 receptor agonists,1 including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide). These medicines are used for weight loss and for treating type 2 diabetes. The review was triggered by the Icelandic medicines agency following reports of suicidal thoughts and self-injury in people using liraglutide and semaglutide medicines. So far authorities have retrieved and are analysing about 150 reports of possible cases of self-injury and suicidal thoughts. Liraglutide and semaglutide medicines are widely used, with an exposure of over 20 million patient- years2 to date. It is not yet clear whether the reported cases are linked to the medicines themselves or to the patients’ underlying conditions or other factors. The review is being carried out in the context of a signal procedure. A signal is information on a new adverse event that is potentially caused by a medicine or a new aspect of a known adverse event that warrants further investigation. The presence of a signal does not necessarily mean that a medicine caused the adverse event in question. Saxenda and Wegovy are authorised for weight management, together with diet and physical activity in people who are obese or overweight in the presence of at least one weight-related health problem. Ozempic is authorised for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise but has been used off-label for weight loss. Suicidal behaviour is not currently listed as a side effect in the EU product information for any GLP-1 receptor agonists. The review of Ozempic, Saxenda and Wegovy started on 3 July 2023 and has now been extended to include other GLP-1 receptor agonists. This review is expected to conclude in November 2023.

  • 21 July, 09:17
  • Read more
Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech